X0306 4 2013-01-18 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532219 Quinn Anthony 128 SPRING STREET, SUITE 520 LEXINGTON MA 02421 false true false false SVP, Chief Medical Officer Common Stock 2013-01-18 4 M false 9447 0.95 A 24482 D Common Stock 2013-01-18 4 S false 9447 50.08 D 15035 D Stock Option (Right to Buy) 0.95 2013-01-18 4 M false 9447 0 D 2019-10-07 Common Stock 9447 38964 D The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2012. The Stock Option granted the reporting person an option to purchase 101,080 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 08/31/2010, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $50.00 to $50.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Anthony Quinn 2013-01-23